<DOC>
	<DOCNO>NCT02718417</DOCNO>
	<brief_summary>This Phase 3 , open-label , international , multi-center , efficacy , safety study avelumab combination and/or follow platinum-based chemotherapy . Eligible patient must previously untreated , histologically confirm Stage III-IV epithelial ovarian ( EOC ) , fallopian tube cancer ( FTC ) , primary peritoneal cancer ( PPC ) candidate platinum-based chemotherapy . The primary purpose study demonstrate avelumab give single agent maintenance set follow frontline chemotherapy combination carboplatin/paclitaxel superior platinum-based chemotherapy alone follow observation population newly diagnose ovarian cancer patient .</brief_summary>
	<brief_title>Avelumab Previously Untreated Patients With Epithelial Ovarian Cancer ( JAVELIN OVARIAN 100 )</brief_title>
	<detailed_description />
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Neoplasms , Glandular Epithelial</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Key Histologically confirm Stage IIIIV epithelial ovarian , fallopian tube , primary peritoneal cancer , include malignant mixed Müllerian tumor high grade serous component Patients must candidate platinum base chemotherapy previously untreated Patients must complete surgical debulking procedure , candidate neoadjuvant chemotherapy Availability archival formalin fix , paraffin embed ( FFPE ) tumor tissue block minimum 15 slide ECOG PS 01 Adequate hematological , renal , liver function Key Non epithelial tumor ovarian tumor low malignant potential ( ie , borderline tumor ) mucinous tumor Prior systemic anticancer treatment EOC , FTC , PPC include prior immunotherapy IL 2 , IFN α , anti PD 1 , anti PD L1 , anti PD L2 , anti CD137 , anti cytotoxic T lymphocyte associate antigen 4 ( anti CTLA 4 ) antibody ( include ipilimumab ) , antibody drug specifically target T cell co stimulation immune checkpoint pathways Patients , opinion Investigator , clinical benefit administer bevacizumab firstline treatment bevacizumab approve available setting . Cancer intraperitoneal cytotoxic chemotherapy plan Active autoimmune disease ( exception include diabetes type I , vitiligo , psoriasis , hypo hyperthyroidism require immunosuppressive treatment )</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>untreated epithelial ovarian</keyword>
	<keyword>fallopian tube</keyword>
	<keyword>primary peritoneal cancer</keyword>
</DOC>